Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dry Eye Disease (DED) Clear all

Conditions: Dry Eye Disease
Interventions: OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo, Placebo (vehicle) nasal spray; Drug · Other
Lead sponsor: Vance Thompson Vision - MT; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Dry Eye
Interventions: Vehicle, SDP-4 Ophthalmic Solution (1.0%); Drug
Lead sponsor: Silk Technologies, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Garden Grove, California • Murrieta, California • Newport Beach, California + 2 more

Conditions: Dry Eye
Interventions: OTX-DED; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 15
States / cities: Inglewood, California • Mission Hills, California • Newport Beach, California + 12 more

Conditions: Dry Eye
Interventions: Miebo, Saline; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 12
States / cities: Glendale, California • Murrieta, California • Newport Beach, California + 9 more

Conditions: Fuchs Endothelial Corneal Dysfunction, Open Angle Glaucoma (OAG), Dry Eye Disease (DED), Keratoconus, Lasik Eye Surgery
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 20 Years to 79 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dry Eye Disease (DED)
Interventions: OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray; Drug
Lead sponsor: Oyster Point Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 22
States / cities: Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 18 more

Conditions: Dry Eye Disease (DED)
Interventions: NOV03, Placebo; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 29
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Glendale, California + 25 more

Conditions: Keratoconjunctivitis Sicca
Interventions: Lotemax, Restasis, Soothe® Lubricant Eye Drops; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 40 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Irvine, California

Conditions: Dry Eye
Interventions: Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose, Corticosteroid Eye Drop; Drug
Lead sponsor: Ocugen; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Hoffman Estates, Illinois • Yorkville, Illinois • Salt Lake City, Utah

Conditions: Dry Eye Disease (DED)
Interventions: 011516X (New Artificial Tear Formulation), Systane Ultra Multidose, REFRESH PLUS®; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 26
States / cities: Azusa, California • Glendale, California • Newport Beach, California + 22 more

Conditions: Dry Eye Disease (DED)
Interventions: Active Comparator EBI-005, Placebo Comparator; Drug
Lead sponsor: Eleven Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 45
States / cities: Chandler, Arizona • Mesa, Arizona • Little Rock, Arkansas + 38 more

Conditions: Dry Eye
Interventions: Optive MEGA-3 (OM3); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Dry Eye Disease (DED)
Interventions: Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML; Device
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 22 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions: Omega-3 EFA Supplement, Olive Oil; Drug
Lead sponsor: Asbell, Penny, M.D.; Individual
Eligibility: 18 Years to 90 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Dry Eye Disease, Endothelial Cell
Interventions: Cyclosporine ophthalmic solution, 0.1%, Saline solution, 0.6%; Drug
Lead sponsor: Novaliq GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: Newport Beach, California • Torrance, California • Garner, North Carolina + 3 more

Conditions: Dry Eye Disease (DED)
Interventions: DFL24498, Vehicle; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 24
States / cities: Chandler, Arizona • Azusa, California • Glendale, California + 21 more

Conditions: MGD-Meibomian Gland Dysfunction
Interventions: Thermal Vectored Pulsation; Device
Lead sponsor: Dunes Eye Consultants; Other
Eligibility: 25 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dakota Dunes, South Dakota

Conditions: Dry Eye Disease
Interventions: ST-100 (vezocolmitide), Vehicle; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Dry Eye Disease
Interventions: glycerin 0.7%/PEG 400 0.3%, polyethylene glycol 400 0.4%/propylene glycol 0.3%; Drug
Lead sponsor: Calm Water Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Dry Eye Syndrome (DES), Dry Eye Disease (DED)
Interventions: Miebo four times per day; Drug
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Bozeman, Montana • Omaha, Nebraska • Fargo, North Dakota + 1 more

Conditions: Dry Eye Disease
Interventions: licaminlimab, vehicle of OCS-02, Artificial tears; Drug · Other
Lead sponsor: Oculis; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Newport Beach, California • Colorado Springs, Colorado • Shelby, North Carolina + 2 more

Conditions: Dry Eye Syndromes
Interventions: Cyclosporine A, Placebo; Drug
Lead sponsor: Novaliq GmbH; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more

Conditions: Dry Eye
Interventions: AXR-159, Vehicle; Drug
Lead sponsor: AxeroVision, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Andover, Massachusetts • Raynham, Massachusetts • Memphis, Tennessee

Conditions: Eyelid Diseases, Eyelid Movement Disorders, Dry Eye, Dry Eye Syndromes, Skin Laxity
Interventions: TriLift device; Device
Lead sponsor: Lumenis Be Ltd.; Industry
Eligibility: 22 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL

Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)

To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Dry Eye Disease Study With Brimonidine

Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

Phase 3 Study of EBI-005 in Dry Eye Disease

An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

Evaluating Crosslinked Hyaluronate Canalicular Gel for the Treatment of DED in Patients Undergoing Cataract Surgery

Dry Eye Assessment and Management: Feasibility Study

A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED

Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)

Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops

A Multicenter, Open-Label Study to Evaluate Perioperative Treatment of Dry Eye With Miebo® in Subjects Undergoing LASIK

Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease

Feasibility of Dynamic Muscle Stimulation + Radiofrequency for Improving Blink Quality in Subjects with Dry Eye Disease